ABB to Provide Paint Solutions to SAIC Volkswagen’s First Electric Vehicle Factory in China
ABB signed a formal agreement with SAIC Volkswagen to provide robotics painting solutions for the first New Energy Vehicle (NEV) factory of the Volkswagen Group based on the Modular Electric Driver Kit (MEB), an automotive platform specifically designed for the mass production of electric vehicles. Financial details were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190501005430/en/
ABB Robotics painting solutions (Photo: Business Wire)
The new 610,000 square meter NEV factory will be in Shanghai, opening in 2020 with an annual capacity of 300,000 pure electric vehicles from the Audi, Volkswagen and Skoda brands.
This is the first large automated painting project provided by ABB for SAIC Volkswagen. ABB will install approximately 300 robots to provide painting and sealing solutions on three automated painting production lines. These solutions involve automobile exterior and interior painting, underbody painting, interior cosmetic seam sealing and interior plate wax-spraying.
“We are delighted to support China’s rapidly growing electric vehicle industry and to extend our partnership with Volkswagen as the company expands its electric vehicle manufacturing capabilities. This award recognizes ABB’s deep expertise in the electric vehicle segment overall and, in particular, our Robotics automotive expertise supported by global applications centers in China, Europe and the United States,” said Sami Atiya, President of ABB’s Robotics and Discrete Automation business.
Chen Hong, President of SAIC Group said: “Unprecedented changes are taking place in the automobile industry, and electrification and digitalization are inevitable trends. SAIC Volkswagen is actively participating in this change. The NEV plant is an important part of completing SAIC Volkswagen's strategic layout for the future. The NEV plant will become an intelligent, flexible and agile electric vehicle production base of SAIC Volkswagen, helping the company to become the leader in the electric vehicle market in terms of technology and sales volume. It will bring diversified choices with advanced technology and reliable performance to Chinese consumers.”
The RMB 17 billion factory is a modern green benchmark factory combining intelligent manufacturing and environmentally-friendly technologies with a special focus on water preservation, energy savings and the reduction of carbon dioxide.
Environmentally-friendly solutions are at the heart of the ABB installation. The painting solutions ABB provides will meet Volkswagen’s 2010v environmental standards, the world’s leading waterborne painting process. The primerless painting technology employed in the process can improve paint utilization rates and reduce waste.
Compared with the traditional painting process, it adopts a dry spray absorption system instead of a water circulation system, which can circulate air and use limestone to absorb the spray, so the use of water is no longer necessary. Some 95 percent of the air can be reused and the limestone can be recycled resulting in energy savings of up to 60 percent. The emission of volatile organic compounds (VOC) can also be reduced by 63 percent.
At the same time, through the rapid acceleration of ABB robots, large flow and fine control of ABB atomizers and the deep application experience of ABB’s engineering team, the total cycle time of the three painting production lines will reach 120 Jobs Per Hour (JPH), the fastest in a single paint shop. In addition, all ABB robots will be able to be connected to ABB AbilityTM digital solutions to prepare for the future digital deployment of the factory.
As the world leader in electric vehicle infrastructure, ABB has sold 10,500 DC chargers, including high power chargers up to 350 kW, across 73 countries – more than any other manufacturer. ABB entered the EV-charging market in 2010 and offers the full range of charging solutions for electric cars, electric and hybrid buses as well as electrification solutions for ships and railways.
ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, ABB is active in 53 countries and over 100 locations and has shipped over 400,000 robot solutions for a diverse range of industries and applications. ABB helps its customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market-leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
8050 Zurich Switzerland
Phone: +41 43 317 71 11
Phone: +41 43 317 71 11
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CEST | Press release
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti
Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CEST | Press release
In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CEST | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp
Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family11.10.2019 02:00:00 CEST | Press release
Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/ Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation) This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability. Development Background Advanced proces
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis10.10.2019 22:00:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/ “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.” “The
Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 201910.10.2019 20:05:00 CEST | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the con